Acquisitions - Symbiosys Acquisition - Fair Value of Consideration (Details) - Symbiosys Acquisition $ in Millions |
May 28, 2025
USD ($)
|
|---|---|
| Business Combination [Line Items] | |
| Cash | $ 89 |
| Deferred cash consideration | 29 |
| Fair value of previously held equity interest | 3 |
| Total consideration | $ 121 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Fair value at acquisition date of equity interest in acquiree held by acquirer immediately before acquisition date in business combination achieved in stages. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|